(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat ...

Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...

Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes ...

French pharma giant Sanofi (NASDAQ:SNY) has agreed to sell global rights linked to Enjaymo, an FDA-approved treatment for an ...

Recordati SpA is shelling out $825 million up front for global rights to Enjaymo (sutimlimab), the only therapy approved for treating the rare disease cold agglutinin disease. In the deal with Sanofi ...

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...

Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed ...

Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic ...

Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to ...

Analyst Derek Archila of Wells Fargo maintained a Buy rating on Annexon Biosciences (ANNX – Research Report), retaining the price target ...

Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold ...